Skip to main content
ISOP ACoP 2025 Annual Conference Main banner

Sandra Visser, PhD (she/her/hers)

Founder
QUANTIVIS LLC

Sandra Visser, Ph.D., brings over two decades of extensive experience in quantitative medicine and strategic drug discovery and development with a passion to accelerate the development of novel therapies and improve patient outcomes. She recently founded QUANTIVIS LLC, aiming to advise biotech companies to unlock the value of quantitative medicine. As such, she continues to support Alltrna, a tRNA biotech company aiming to treat rare genetic diseases. Previously, Sandra has held leadership roles in both biotech and large pharma companies (Alltrna, GSK, Merck, and AstraZeneca), where she and her teams successfully advanced preclinical and clinical drug projects and supported several successful marketing applications, using clinical and quantitative translational pharmacology concepts across diverse therapeutic areas, including oncology, cardiometabolic, neuroscience and rare metabolic diseases. Through her career, she has been recognized for her pivotal contributions to model informed drug discovery and development (MID3) and the integration of biomarker data into mathematical models to optimize dose selection, accelerate clinical trial design, and enhance regulatory submissions. She currently servies as the President of the American Society of Clinical Pharmacology and Therapeutics. Sandra earned her M.Sc. in Bio-Pharmaceutical Sciences and Ph.D. in Quantitative Pharmacology from Leiden University in the Netherlands. She has published over 65 peer-reviewed scientific articles and has been an editor and reviewer for several scientific journals

Disclosure information not submitted.

Presentation(s):

Email Sandra